Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The adenosine A<sub>2A</sub> receptor antagonist KW6002 mitigates aldosterone-induced central serous chorioretinopathy in mice.

Neuropharmacology·2026
Same author

Discovery of Trolox amide derivatives as potent membrane-targeted ferroptosis inhibitors for corneal injury therapy.

European journal of medicinal chemistry·2026
Same author

Adenosine signaling: the convergent hub in antidepressant action.

Trends in molecular medicine·2026
Same author

40 Hz light flickering alleviates chronic pain via adenosine signaling in the retina-amygdala pathway.

Cell research·2026
Same author

Homeostatic adenosine signaling unifies rapid antidepressant actions of ketamine, electroconvulsive therapy and hypoxia.

Science bulletin·2026
Same author

40 Hz flicker preconditioning protects nonarteritic anterior ischemic optic neuropathy via adenosine signaling.

Communications biology·2026

Related Experiment Video

Updated: May 9, 2026

Targeted Knockdown of Genes in the Choroid Plexus
04:43

Targeted Knockdown of Genes in the Choroid Plexus

Published on: June 16, 2023

Adenosine A2A receptor deficiency alleviates blast-induced cognitive dysfunction.

Ya-Lei Ning1, Nan Yang, Xing Chen

  • 1Molecular Biology Center, State Key Laboratory of Trauma, Burn, and Combined Injury, Research Institute of Surgery and Daping Hospital, Third Military Medical University, Chongqing, China.

Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|August 8, 2013
PubMed
Summary

Adenosine A2A receptor (A2AR) antagonism may treat blast-induced traumatic brain injury (bTBI). Blocking A2AR in mice reduced bTBI cognitive deficits and neuropathology, suggesting a therapeutic target.

More Related Videos

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo
06:24

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo

Published on: July 8, 2025

Related Experiment Videos

Last Updated: May 9, 2026

Targeted Knockdown of Genes in the Choroid Plexus
04:43

Targeted Knockdown of Genes in the Choroid Plexus

Published on: June 16, 2023

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo
06:24

Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo

Published on: July 8, 2025

Area of Science:

  • Neuroscience
  • Traumatic Brain Injury Research
  • Pharmacology

Background:

  • Blast-induced traumatic brain injury (bTBI) is a prevalent injury in military personnel.
  • Cognitive dysfunction following bTBI has long-lasting effects, impacting military and civilian life.
  • Mechanisms underlying bTBI-induced cognitive deficits are poorly understood, and effective treatments are lacking.

Purpose of the Study:

  • To investigate the role of the adenosine A2A receptor (A2AR) in bTBI-induced cognitive impairment.
  • To explore the underlying neuropathological mechanisms influenced by A2AR in bTBI.
  • To evaluate A2AR antagonism as a potential therapeutic strategy for bTBI.

Main Methods:

  • Utilized a mouse model of moderate whole-body blast injury.
  • Compared cognitive function (spatial reference and working memory) between A2AR knockout (KO) mice and wild-type mice post-bTBI.
  • Assessed neuropathological markers including cortical and hippocampal lesions, cytokine expression, glutamate release, edema, cell loss, and gliosis.

Main Results:

  • A2AR KO mice exhibited reduced severity and duration of cognitive deficits compared to wild-type mice after bTBI.
  • bTBI-induced cortical and hippocampal damage, inflammation, excitotoxicity, edema, cell death, and gliosis were significantly attenuated in A2AR KO mice.
  • These protective effects were observed in both early and prolonged phases following the injury.

Conclusions:

  • Early injury and chronic neuropathological damage are key contributors to bTBI-induced cognitive impairment.
  • Preventing A2AR activation can attenuate cognitive deficits and neuropathology following bTBI.
  • A2AR antagonism represents a promising therapeutic strategy for managing mild-to-moderate bTBI and associated cognitive impairments.